Header Logo

Connection

Jeff Slezak to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Jeff Slezak has written about Prostatic Neoplasms.
Jeff Slezak
Connection Strength
4.633
Prostatic Neoplasms
  1. Antidepressant medication use and prostate cancer recurrence in men with depressive disorders. Cancer Causes Control. 2022 Nov; 33(11):1363-1372.
    View in: PubMed
    Score: 0.686
  2. Long-term follow-up of a racially and ethnically diverse population of men with localized prostate cancer who did not undergo initial active treatment. Cancer Med. 2020 11; 9(22):8530-8539.
    View in: PubMed
    Score: 0.599
  3. Salvage Cryoablation for Radiorecurrent Prostate Cancer: Initial Experience at a Regional Health Care System. Perm J. 2019; 23.
    View in: PubMed
    Score: 0.133
  4. Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population. BJU Int. 2017 10; 120(4):520-529.
    View in: PubMed
    Score: 0.118
  5. Effect of a Smoking Cessation Program on Sexual Function Recovery Following Robotic Prostatectomy at Kaiser Permanente Southern California. Perm J. 2017; 21:16-138.
    View in: PubMed
    Score: 0.116
  6. Ten-Year Trends in Preventive Service Use Before and After Prostate Cancer Diagnosis: A Comparison with Noncancer Controls. Perm J. 2017; 21:16-184.
    View in: PubMed
    Score: 0.116
  7. Treatment results of brachytherapy vs. external beam radiation therapy for intermediate-risk prostate cancer with 10-year followup. Brachytherapy. 2016 Nov - Dec; 15(6):687-694.
    View in: PubMed
    Score: 0.113
  8. The effect of urologist experience on choosing active surveillance for prostate cancer. World J Urol. 2015 Nov; 33(11):1701-6.
    View in: PubMed
    Score: 0.102
  9. Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol. 2014 Jul 29; 9:171.
    View in: PubMed
    Score: 0.098
  10. Extracting data from electronic medical records: validation of a natural language processing program to assess prostate biopsy results. World J Urol. 2014 Feb; 32(1):99-103.
    View in: PubMed
    Score: 0.088
  11. Correlates of prostate-specific antigen testing in a large multiethnic cohort. Am J Manag Care. 2009 Nov; 15(11):793-9.
    View in: PubMed
    Score: 0.070
  12. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol. 2009 Aug; 182(2):517-25; discussion 525-7.
    View in: PubMed
    Score: 0.068
  13. Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res. 2008 Mar 15; 14(6):1734-43.
    View in: PubMed
    Score: 0.063
  14. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int. 2008 Jan; 101(2):170-4.
    View in: PubMed
    Score: 0.062
  15. Increased optical magnification from 2.5x to 4.3x with technical modification lowers the positive margin rate in open radical retropubic prostatectomy. J Urol. 2008 Jan; 179(1):130-5.
    View in: PubMed
    Score: 0.061
  16. Population-based case-control study of PSA and DRE screening on prostate cancer mortality. Urology. 2007 Nov; 70(5):936-41.
    View in: PubMed
    Score: 0.061
  17. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol. 2007 Aug; 178(2):459-63; discussion 463.
    View in: PubMed
    Score: 0.060
  18. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc. 2007 Apr; 82(4):422-7.
    View in: PubMed
    Score: 0.059
  19. Radical prostatectomy for octogenarians: how old is too old? Urology. 2006 Nov; 68(5):1042-5.
    View in: PubMed
    Score: 0.057
  20. Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. Urology. 2006 Sep; 68(3):604-8.
    View in: PubMed
    Score: 0.057
  21. Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. J Urol. 2006 Sep; 176(3):1118-21.
    View in: PubMed
    Score: 0.056
  22. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer. 2006 Aug 01; 107(3):521-9.
    View in: PubMed
    Score: 0.056
  23. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. J Urol. 2006 Aug; 176(2):559-63.
    View in: PubMed
    Score: 0.056
  24. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer. 2006 Jun 15; 106(12):2630-5.
    View in: PubMed
    Score: 0.056
  25. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol. 2006 Mar; 175(3 Pt 1):952-7.
    View in: PubMed
    Score: 0.055
  26. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol. 2006 Feb; 175(2):547-51.
    View in: PubMed
    Score: 0.054
  27. Simple graphic method for estimation of prostate-specific antigen doubling time. Urology. 2006 Feb; 67(2):408-9.
    View in: PubMed
    Score: 0.054
  28. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005 Dec; 174(6):2191-6.
    View in: PubMed
    Score: 0.054
  29. Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000. BJU Int. 2005 May; 95(7):951-5.
    View in: PubMed
    Score: 0.051
  30. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol. 2005 Apr; 173(4):1121-5.
    View in: PubMed
    Score: 0.051
  31. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005 Apr; 95(6):751-6.
    View in: PubMed
    Score: 0.051
  32. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol. 2004 Dec; 172(6 Pt 1):2244-8.
    View in: PubMed
    Score: 0.050
  33. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004 Oct; 172(4 Pt 1):1328-32.
    View in: PubMed
    Score: 0.049
  34. An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays. Am J Clin Pathol. 2004 Feb; 121(2):220-5.
    View in: PubMed
    Score: 0.047
  35. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003 Nov; 170(5):1872-6.
    View in: PubMed
    Score: 0.046
  36. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer. 2002 Sep 15; 95(6):1215-9.
    View in: PubMed
    Score: 0.043
  37. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol. 2002 Sep; 168(3):1204-11.
    View in: PubMed
    Score: 0.043
  38. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer. 2002 Aug; 34(4):363-71.
    View in: PubMed
    Score: 0.043
  39. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol. 2002 Aug; 168(2):525-9.
    View in: PubMed
    Score: 0.043
  40. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002 Jan; 167(1):117-22.
    View in: PubMed
    Score: 0.041
  41. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol. 2002 Jan; 15(1):35-44.
    View in: PubMed
    Score: 0.041
  42. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001 Jun; 57(6):1033-7.
    View in: PubMed
    Score: 0.039
  43. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001 Jun; 76(6):576-81.
    View in: PubMed
    Score: 0.039
  44. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000 Nov; 164(5):1591-5.
    View in: PubMed
    Score: 0.038
  45. Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. J Clin Oncol. 2000 Aug; 18(15):2862-8.
    View in: PubMed
    Score: 0.037
  46. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000 Jul; 164(1):101-5.
    View in: PubMed
    Score: 0.037
  47. Extranodal extension in lymph node-positive prostate cancer. Mod Pathol. 2000 Feb; 13(2):113-8.
    View in: PubMed
    Score: 0.036
  48. Fluorescence in situ hybridization aneuploidy as a predictor of clinical disease recurrence and prostate-specific antigen level 3 years after radical prostatectomy. Mayo Clin Proc. 1999 Dec; 74(12):1214-20.
    View in: PubMed
    Score: 0.035
  49. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer. 1999 Nov 01; 86(9):1775-82.
    View in: PubMed
    Score: 0.035
  50. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst. 1999 Sep 15; 91(18):1574-80.
    View in: PubMed
    Score: 0.035
  51. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999 Sep; 54(3):479-85.
    View in: PubMed
    Score: 0.035
  52. Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer. 1999 Aug 15; 86(4):657-63.
    View in: PubMed
    Score: 0.035
  53. Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. Am J Surg Pathol. 1999 Jul; 23(7):803-8.
    View in: PubMed
    Score: 0.034
  54. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology. 1999 Jul; 54(1):105-10.
    View in: PubMed
    Score: 0.034
  55. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol. 1999 Apr; 161(4):1223-7; discussion 1227-8.
    View in: PubMed
    Score: 0.034
  56. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol. 1999 Apr; 161(4):1229-32.
    View in: PubMed
    Score: 0.034
  57. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery. J Urol. 1999 Apr; 161(4):1233-7.
    View in: PubMed
    Score: 0.034
  58. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer. 1999 Mar 15; 85(6):1293-9.
    View in: PubMed
    Score: 0.034
  59. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol. 1999 Mar; 161(3):857-62; discussion 862-3.
    View in: PubMed
    Score: 0.034
  60. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol. 1998 Dec; 22(12):1491-500.
    View in: PubMed
    Score: 0.033
  61. Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer. 1998 Nov 15; 83(10):2164-71.
    View in: PubMed
    Score: 0.033
  62. Pathologic classification of prostate carcinoma: the impact of margin status. Cancer. 1998 Mar 01; 82(5):902-8.
    View in: PubMed
    Score: 0.031
  63. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 1997 Nov; 50(5):733-9.
    View in: PubMed
    Score: 0.031
  64. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol. 1997 Nov; 15(4):222-9.
    View in: PubMed
    Score: 0.031
  65. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001 Apr; 165(4):1146-51.
    View in: PubMed
    Score: 0.010

© 2024 Kaiser Permanente